We seek to understand the molecular processes of aging that drive Alzheimer's disease (AD), and to define the therapeutic potential of drug candidate molecules in treating AD.
We use genetic manipulations in rodents, in vivo optical and MRI- and PET-based brain imaging, laser Doppler-based cerebral blood flow measures, primary cell culture systems and a range of biochemical, cellular and molecular biology approaches, together with single-cell -omic and behavioral tools.
Our ultimate goal is to advance our understanding of age-related neurodegenerations, including AD, and to identify potential interventions to treat them or delay their progression.
 

​

​

​